bevacizumab

Ligand id: 6771

Name: bevacizumab

References
1. Baca M, Chen Y M-Y, Lowman HB, Presta LG, Wells JA. (1998)
Anti-vegf antibodies.
Patent number: WO1998045331. Assignee: Genentech Inc,. Priority date: 07/04/1997. Publication date: 15/10/1998.
2. FDA. 
FDA approves bevacizumab in combination with chemotherapy for ovarian cancer.
Accessed on 18/06/2018. Modified on 18/06/2018. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm?utm_campaign=Oncology%206%2F13%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=aedf1123feb446ac8126d28a2d6ce8d7&elq=7a1e38bda6884f40bcc462e71a154a89&elqaid=3898&elqat=1&elqCampaignId=3025
3. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003)
VEGF blocking therapy in the treatment of cancer.
Expert Opin Biol Ther, 3 (2): 263-76. [PMID:12662141]
4. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016)
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Ann. Oncol., 27 (1): 114-21. [PMID:26487588]
5. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N. Engl. J. Med., 349 (5): 427-34. [PMID:12890841]